Background: Germ-line mutations in BRCA1/2 (gBRCAm) can cause defective repair of double-strand DNA breaks and are a risk factor for mPC. The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib exploits homologous recombination repair deficiency in BRCAm tumors to produce synthetic lethality. Its efficacy is being evaluated in the POLO trial (NCT02184195). It is unknown how geography and ethnicity impact uptake of gBRCAm pre-screening in mPC. Methods: POLO is an international, ongoing, placebo-controlled trial to determine efficacy of olaparib (tablet formulation) maintenance monotherapy in gBRCAm pts with mPC. Mandatory pre-screening involves gBRCA testing by Integrated BRACAnalysis (Myriad Genetic Laboratories/MGL). The current analysis includes pts with gBRCAm previously identified by MGL or via pre-screening. Demographic/clinical history data were collected at enrollment. Results: 2206 pts from 12 countries were tested between 10/14 and 12/17. Pre-screening identified 130/2179 (6.0%) with a new gBRCAm; 27 additional pts had a previously known gBRCAm that were confirmed by Myriad testing; total 159/2206 (7.2%). Pre-screened pts were 57.2% male; 21% had early-onset mPC (Age in yrs: < 33: 0.6%; 33-49: 20.3%; 50-64: 49.4%; 65-88: 29.7%). gBRCAm pts were younger (57.9 vs. 61.1 yrs).The countries with the highest rates of new gBRCAm by pre-screening were: USA 37/288 (12.8%), Israel 26/230 (11.3%), France 24/293 (8.1%), Germany 17/262 (6.4%), Italy 15/250 (6%), Spain 14/344 (4%), and Korea 10/196 (5.1%). Outside US and Israel (populations enriched in Ashkenazi Jews), gBRCAm was newly identified in 96/1668 (5.75%). All pts with a known gBRCAm were White; all gBRCAm in African American/Asian/Hispanic pts (n = 19) were first identified by pre-screening. Conclusions: 6-7% unselected mPC have gBRCAm, with substantial geographic variability. Pts with gBRCAm were diagnosed at younger ages. Non-White pts were universally unaware of familial gBRCAm before pre-screening, highlighting potential disparities in uptake of genetic testing in minority populations and emphasizing the need to improve access to testing. Clinical trial information: NCT02184195